Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses an exciting preclinical investigation of the safety and tolerability of a BCMAxCD3 bispecific antibody for the treatment of multiple myeloma (MM). This form of therapy redirects T-cells to myeloma cells, and is considered to be efficacious in newly diagnosed patients, heavily pre-treated patients, and patients that are refractory to all available therapies, including lenalidomide, pomalidomide and bortezomib. In the future, this drug may be considered for MM patients with detectable minimal residual disease (MRD) after transplant or reinduction therapy. This interview was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
T-cell redirecting therapies for R/R multiple myeloma
